Bristol Myers posts quarterly loss, revenue increases by 5%
Bristol Myers Squibb revealed a first-quarter misfortune on Thursday as costs connected with its new acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% ascent in deals. Bristol Myers read more..